Renin-angiotensin system (RAS) inhibitors slow CKD advancement but are often discontinued if acute decreases in estimated glomerular filtration rate (eGFR) occur after initiation. Elaine Ku, MD, and colleagues questioned whether this practice is optimal and compared the kidney, cardiovascular, and mortality risks linked to discontinuing versus continuing RAS inhibitors in this scenario.
Researchers conducted the retrospective cohort study, leveraging electronic records from the Manitoba Centre for Health Policy in Canada. They applied propensity score matching to pinpoint adults (aged ≥18 years) who were given new prescriptions for RAS inhibitors and experienced an eGFR decrease of more than 15% within 90 days. The participants received the medications between January 1, 2008, and December 31, 2021, and the investigators analyzed the data between January 14, 2024, and January 22, 2026. Discontinuation versus continuation was determined based on whether participants refilled their prescription after 90 days following a 15% decline in eGFR. Cox proportional hazard models were used to compare exposure with outcomes.
Primary outcomes were end-stage kidney disease (ESKD) or death. Secondary outcomes were acute kidney injury (AKI) or major adverse cardiovascular events (MACE) occurring within 180 days.
Among 4,233 participants, 1,411 (33.3%) discontinued RAS inhibitors, and 2,822 (66.6%) continued them. Those who discontinued RAS inhibitors had a higher risk for ESKD (hazard ratio [HR], 1.74; 95% CI, 1.28-2.38) and death (HR, 1.23; 95% CI, 1.07-1.41). However, the patients who discontinued RAS inhibitors did not have a significantly higher risk for AKI (HR, 1.11; 95% CI, 0.90-1.37) or MACE (HR, 1.13; 95% CI, 0.99-1.28).
Since continuing RAS inhibitors is linked to a lower risk for ESKD and death, future research should explore the reasons for frequent discontinuation and identify strategies to prolong the use of RAS inhibitors, the authors concluded.